How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    2 The condition, current treatments and procedure

    The condition

    2.1 Osteoarthritis is characterised by localised loss of cartilage, remodelling of adjacent bone and associated inflammation. Knees are one of the most affected joints, with pain being a significant symptom.

    2.2 Angiogenesis is believed to contribute to inflammation, structural damage and pain. This is because the increased vascular network carries inflammatory cells to the synovium and other joint tissues and promotes additional hyperplasia and inflammation in other vessels, leading to bone and cartilage destruction. Angiogenesis also enables the growth of new unmyelinated sensory nerves, which contributes to pain.

    Current treatments

    2.3 For pain secondary to knee osteoarthritis, various treatments are available including nonpharmacologic (such as physiotherapy), pharmacologic (such as analgesics and hyaluronic acid injections) and surgical approaches (such as knee arthroplasty).

    2.4 Treatment most commonly involves a combination of pharmacologic therapies and non-pharmacologic interventions. When nonpharmacologic and pharmacologic interventions do not work or symptoms are severe, surgery may be needed.

    The procedure

    2.5 This procedure aims to relieve pain by embolising the pathological new vessels while maintaining the larger vascular supply to the bone.

    2.6 Before the procedure, contrast-enhanced magnetic resonance imaging (MRI) of the knee is done to allow non-invasive assessment of synovial hypervascularity. The procedure is usually done using local anaesthesia with or without sedation. A catheter is passed through an introducer sheath in the femoral artery and then navigated into the genicular arteries supplying the knee to perform lower extremity angiography on the targeted side. Once the abnormal new vessels arising from these arteries are identified, a microcatheter is navigated into them and, under fluoroscopic guidance, tiny embolisation particles are then delivered until the blood flow is stopped.

    2.7 After the introducer sheath and catheter are removed, haemostasis is achieved with manual compression or a vascular closure device. The patient often goes home the same day. This procedure generally takes between 45 and 90 minutes.